News25/Ratings2
News · 26 weeks36-57%
2025-12-282026-06-21
Mix2590d
- SEC Filings9(36%)
- Insider8(32%)
- Other5(20%)
- Earnings3(12%)
Latest news
25 items- SECSANUWAVE Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
- PRSanuwave Health Updates Second Quarter 2026 GuidanceSanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $8.5 to $9.5 million, below the guidance provided on the Q1 earnings call on May 13 of this year. "In the time since we had our Q1 call, we have seen material changes in the conditions in the capital equipment market f
- SECSANUWAVE Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
- SECSEC Form SD filed by SANUWAVE Health Inc.SD - SANUWAVE Health, Inc. (0001417663) (Filer)
- PRSanuwave Announces Revenues and Financial Results for Q1 FY2026Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025. GAAP Operating Loss was $1.1 million for Q1 2026, a swing of $1.7 million from operating income of $0.6 million in Q1 2025. Company provides guidance for revenue growth of 10-15% for Q2 2026 as compared to Q2 2025 EDEN PRAIRIE, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended March 31, 2026
- SECSANUWAVE Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
- SECSEC Form 10-Q filed by SANUWAVE Health Inc.10-Q - SANUWAVE Health, Inc. (0001417663) (Filer)
- PRSanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial ResultsEDEN PRAIRIE, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Wednesday, May 13, 2026, at 8:30 AM (ET) to present its Q1 2026 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-833-316-1983 Toll/International: 1-785-838-9310 Conference ID: SANUWAVE OR click the link below to access the live webcast:https://viavid.webcasts.com/starthere.jsp?ei=1762392&tp_key=537d7338d6 Materials for the conference call will be included on the
- INSIDERLarge owner Opaleye Management Inc. sold $574,240 worth of shares (35,581 units at $16.14) (SEC Form 4)4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SANUWAVE Health Inc.SCHEDULE 13G/A - SANUWAVE Health, Inc. (0001417663) (Subject)
- INSIDERLarge owner Opaleye Management Inc. sold $1,274,971 worth of shares (70,648 units at $18.05) (SEC Form 4)4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- SECSEC Form DEFA14A filed by SANUWAVE Health Inc.DEFA14A - SANUWAVE Health, Inc. (0001417663) (Filer)
- SECSEC Form DEF 14A filed by SANUWAVE Health Inc.DEF 14A - SANUWAVE Health, Inc. (0001417663) (Filer)
- INSIDERSEC Form 4 filed by Opaleye Management Inc.4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- SECSANUWAVE Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
- PRSanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-YearSanuwave is pleased to announce preliminary revenues of $9.6 million to $9.7 million for the first quarter ended March 31, 2026, in line with prior guidance for Q1. EDEN PRAIRIE, Minn., April 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the first quarter of 2026 are expected to be in the range of $9.6 to $9.7 million, an increase of 3-4% over Q1 2025. This number is within the range of guidance given in the Company's Q4 2025 earnings release issued on March 26, 2026. "At the end of Q1 the Company saw several good-size
- INSIDERSEC Form 4 filed by Tyler James4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Frank Morgan C.4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Blizard Jeffrey4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Bazar Gregory Matthew4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Miller Ian D.4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SANUWAVE Health Inc.SCHEDULE 13G/A - SANUWAVE Health, Inc. (0001417663) (Subject)
- SECSANUWAVE Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
- PRSanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025Q4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time annual record for the Company. Q4 2025 gross margin was 74.7%, versus 77.9% in Q4 2024 and 77.6% in Q3 2025. Full year 2025 gross margin was 77.1% versus 75.2% in 2024. GAAP Operating Income was $2.0 million for Q4 2025 and $4.9 million for full year 2025. Company provides guidance for revenues of $9.6-10.3 million (an increase of 3-10%) for Q1 2026 as compared to Q1 2025 and initiates full year 2026 revenue guidance of 16-25% growth vs 2025 ($51.0-55.0 million). EDEN
- SECSEC Form 10-K filed by SANUWAVE Health Inc.10-K - SANUWAVE Health, Inc. (0001417663) (Filer)
SNWV FAQ
5 questionsWhere does SNWV stock trade?
SANUWAVE Health Inc. (SNWV) is listed on NASDAQ.What sector and industry is SNWV in?
SANUWAVE Health Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about SNWV?
SANUWAVE Health Inc. has had 2 recent analyst actions on file. The most recent action was from Northland Capital: Outperform on 2025-09-03. Recent price targets cluster around $4900.00.What companies are similar to SNWV?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare SNWV side-by-side with any of them on Quantisnow.How can I track SNWV on Quantisnow?
Quantisnow aggregates SANUWAVE Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNWV to receive live email and push alerts on every new disclosure.